Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.
You may also be interested in...
One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.